Clovis Oncology (CLVS) and Isotopia Announce Lutetium-177 Clinical Supply Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement
September 21, 2022 8:00 AM EDTIsotopia to supply its medical radioisotope, lutetium-177, for the clinical development of Clovis Oncologys targeted radionuclide therapy candidate FAP-2286
BOULDER, Colo. & PETACH TIKVA, Israel--(BUSINESS WIRE)-- Clovis Oncology, Inc. (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that provides Clovis Oncology with... More
